AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Acalabrutinib Real World Italian obSErvational Study -ARISE
Recruiting
- Conditions
- Chronic Lymphocytic Leukemia
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 190
- Registration Number
- NCT06205498
- Locations
- 🇮🇹
Research Site, Viterbo, Italy
Observational Secondary Data Study Describing Treatment With Dapagliflozin Among Adult Chronic Kidney Disease Patients
Recruiting
- Conditions
- Chronic Kidney Disease (CKD)
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1090
- Registration Number
- NCT06203704
- Locations
- 🇸🇮
Research Site, Zagorje, Slovenia
EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy
Phase 3
Active, not recruiting
- Conditions
- Transthyretin Amyloid Cardiomyopathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT06194825
- Locations
- 🇨🇳
Research Site, Xi'an, China
A Study to Investigate the Effect on QTcF of Baxdrostat Compared With Placebo, Using Moxifloxacin as a Positive Control, in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT06194032
- Locations
- 🇩🇪
Research Site, Berlin, Germany
LTFU for All Cell and Gene Therapy Studies
Not yet recruiting
- Conditions
- Hepatocellular CarcinomaProstate Cancer
- Interventions
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 64
- Registration Number
- NCT06194461
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
Phase 2
Recruiting
- Conditions
- Lung Cancer
- Interventions
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 70
- Registration Number
- NCT06194448
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILD
Active, not recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Other: None (Observational Study)
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 83
- Registration Number
- NCT06192004
- Locations
- 🇺🇸
Research Site, Odessa, Texas, United States
UNFOLD Study Egypt
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 405
- Registration Number
- NCT06188494
- Locations
- 🇪🇬
Research Site, Sohag, Egypt
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
Phase 1
Recruiting
- Conditions
- High-grade Serous Ovarian Cancer (HGSOC)ER+ HER2- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 348
- Registration Number
- NCT06188520
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
A National, Multicenter, Prospective, Observational Study to Assess Patient Characteristics, Treatment Algorithms and Disease Management of Hyperkalaemia Patients With Chronic Kidney Disease or Under Dialysis or With Heart Failure, Treated With Sodium Zirconium Cyclosilicate in Greece
Completed
- Conditions
- Hyperkalaemia
- Interventions
- Drug: sodium zirconium cyclosilicate (SZC)
- First Posted Date
- 2023-12-29
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 125
- Registration Number
- NCT06185660
- Locations
- 🇬🇷
Research Site, Thessaloniki, Greece
© Copyright 2025. All Rights Reserved by MedPath